Cargando…
Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro
INTRODUCTION: The aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogene...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925396/ https://www.ncbi.nlm.nih.gov/pubmed/33681155 http://dx.doi.org/10.3389/fbioe.2021.599224 |
_version_ | 1783659261922902016 |
---|---|
author | Kyyak, Solomiya Blatt, Sebastian Schiegnitz, Eik Heimes, Diana Staedt, Henning Thiem, Daniel G. E. Sagheb, Keyvan Al-Nawas, Bilal Kämmerer, Peer W. |
author_facet | Kyyak, Solomiya Blatt, Sebastian Schiegnitz, Eik Heimes, Diana Staedt, Henning Thiem, Daniel G. E. Sagheb, Keyvan Al-Nawas, Bilal Kämmerer, Peer W. |
author_sort | Kyyak, Solomiya |
collection | PubMed |
description | INTRODUCTION: The aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP-2), and osteonectin (OCN). MATERIALS AND METHODS: Cerabone(®) (CB), Bio-Oss(®) (BO), Creos Xenogain(®) (CX) and MinerOss(®) X (MO) ± i-PRF were incubated with HOB. At day 3, 7, and 10, cell viability and metabolic activity as well as expression of ALP, OCN, and BMP-2, was examined. RESULTS: For non-i-PRF groups, the highest values concerning viability were seen for CB at all time points. Pre-treatment with i-PRF increased viability in all groups with the highest values for CB-i-PRF after 3 and 7 and for CX-i-PRF after 10 days. For metabolic activity, the highest rate among non-i-PRF groups was seen for MO at day 3 and for CB at day 7 and 10. Here, i-PRF groups showed higher values than non-i-PRF groups (highest values: CB + i-PRF) at all time points. There was no difference in ALP-expression between groups. For OCN expression in non-i-PRF groups, CB showed the highest values after day 3, CX after day 7 and 10. Among i-PRF-groups, the highest values were seen for CX + i-PRF. At day 3, the highest BMP-2 expression was observed for CX. Here, for i-PRF groups, the highest increase was seen for CX + i-PRF at day 3. At day 7 and 10, there was no significant difference among groups. CONCLUSION: XBSM sintered under high temperature showed increased HOB viability and metabolic activity through the whole period when compared to XBSM manufactured at lower temperatures. Overall, the combination of XBSM with i-PRF improved all cellular parameters, ALP and BMP-2 expression at earlier stages as well as OCN expression at later stages. |
format | Online Article Text |
id | pubmed-7925396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79253962021-03-04 Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro Kyyak, Solomiya Blatt, Sebastian Schiegnitz, Eik Heimes, Diana Staedt, Henning Thiem, Daniel G. E. Sagheb, Keyvan Al-Nawas, Bilal Kämmerer, Peer W. Front Bioeng Biotechnol Bioengineering and Biotechnology INTRODUCTION: The aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP-2), and osteonectin (OCN). MATERIALS AND METHODS: Cerabone(®) (CB), Bio-Oss(®) (BO), Creos Xenogain(®) (CX) and MinerOss(®) X (MO) ± i-PRF were incubated with HOB. At day 3, 7, and 10, cell viability and metabolic activity as well as expression of ALP, OCN, and BMP-2, was examined. RESULTS: For non-i-PRF groups, the highest values concerning viability were seen for CB at all time points. Pre-treatment with i-PRF increased viability in all groups with the highest values for CB-i-PRF after 3 and 7 and for CX-i-PRF after 10 days. For metabolic activity, the highest rate among non-i-PRF groups was seen for MO at day 3 and for CB at day 7 and 10. Here, i-PRF groups showed higher values than non-i-PRF groups (highest values: CB + i-PRF) at all time points. There was no difference in ALP-expression between groups. For OCN expression in non-i-PRF groups, CB showed the highest values after day 3, CX after day 7 and 10. Among i-PRF-groups, the highest values were seen for CX + i-PRF. At day 3, the highest BMP-2 expression was observed for CX. Here, for i-PRF groups, the highest increase was seen for CX + i-PRF at day 3. At day 7 and 10, there was no significant difference among groups. CONCLUSION: XBSM sintered under high temperature showed increased HOB viability and metabolic activity through the whole period when compared to XBSM manufactured at lower temperatures. Overall, the combination of XBSM with i-PRF improved all cellular parameters, ALP and BMP-2 expression at earlier stages as well as OCN expression at later stages. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7925396/ /pubmed/33681155 http://dx.doi.org/10.3389/fbioe.2021.599224 Text en Copyright © 2021 Kyyak, Blatt, Schiegnitz, Heimes, Staedt, Thiem, Sagheb, Al-Nawas and Kämmerer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Kyyak, Solomiya Blatt, Sebastian Schiegnitz, Eik Heimes, Diana Staedt, Henning Thiem, Daniel G. E. Sagheb, Keyvan Al-Nawas, Bilal Kämmerer, Peer W. Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro |
title | Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro |
title_full | Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro |
title_fullStr | Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro |
title_full_unstemmed | Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro |
title_short | Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro |
title_sort | activation of human osteoblasts via different bovine bone substitute materials with and without injectable platelet rich fibrin in vitro |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925396/ https://www.ncbi.nlm.nih.gov/pubmed/33681155 http://dx.doi.org/10.3389/fbioe.2021.599224 |
work_keys_str_mv | AT kyyaksolomiya activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT blattsebastian activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT schiegnitzeik activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT heimesdiana activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT staedthenning activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT thiemdanielge activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT saghebkeyvan activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT alnawasbilal activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro AT kammererpeerw activationofhumanosteoblastsviadifferentbovinebonesubstitutematerialswithandwithoutinjectableplateletrichfibrininvitro |